At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Market Closed 10-16 16:00:00 EDT
20.30
-1.34
-6.19%
盘后20.30
+0.000.00%
19:30 EDT
High21.60Low20.12Vol1.18M
Open21.60D1 Closing21.64Amplitude6.84%
Mkt Cap1.79BTradable Cap1.34BTotal Shares88.16M
T/O24.21MT/O Rate1.79%Tradable Shares66.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  10-12
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
How Blood Pressure Target Data At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story
Simply Wall St.  ·  10-12
How Blood Pressure Target Data At Mineralys Therapeutics (MLYS) Has Changed Its Investment Story
UBS Initiates a Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  10-12
UBS Initiates a Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
Mineralys Says Phase 3 Launch-HTN Trial Shows 46% of Lorundrostat Patients Hit SBP Target Below 130 mmHg at Week 12
Reuters  ·  10-09
Mineralys Says Phase 3 Launch-HTN Trial Shows 46% of Lorundrostat Patients Hit SBP Target Below 130 mmHg at Week 12
Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative
Simply Wall St.  ·  10-04
Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative
Mineralys Therapeutics CEO Jon Congleton Disposes of $1,909,665 Common Shares
Reuters  ·  10-03
Mineralys Therapeutics CEO Jon Congleton Disposes of $1,909,665 Common Shares
Mineralys Therapeutics to Present New Lorundrostat Launch-HTN Data at ASN Kidney Week 2026
Reuters  ·  10-03
Mineralys Therapeutics to Present New Lorundrostat Launch-HTN Data at ASN Kidney Week 2026
Mineralys to Present Lorundrostat Explore-OSA Hypertension Trial Data at AHA Hypertension Scientific Sessions 2026
Reuters  ·  10-02
Mineralys to Present Lorundrostat Explore-OSA Hypertension Trial Data at AHA Hypertension Scientific Sessions 2026
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-30
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Mineralys Director Brian Taylor Slingsby Disposes of 104,320 Common Shares for $3 Million
Reuters  ·  09-25
Mineralys Director Brian Taylor Slingsby Disposes of 104,320 Common Shares for $3 Million
Mineralys Therapeutics Joins Stifel Virtual Cardiometabolic Forum Fireside Chat
Reuters  ·  09-25
Mineralys Therapeutics Joins Stifel Virtual Cardiometabolic Forum Fireside Chat
Mineralys Says Transform-HTN Extension Data on Lorundrostat Set for Late-Breaking AHA 2026 Presentation
Reuters  ·  09-24
Mineralys Says Transform-HTN Extension Data on Lorundrostat Set for Late-Breaking AHA 2026 Presentation
Mineralys Therapeutics Chief Commercial Officer Eric Warren Disposes of Common Shares Worth USD 209,111.85
Reuters  ·  09-23
Mineralys Therapeutics Chief Commercial Officer Eric Warren Disposes of Common Shares Worth USD 209,111.85
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-22
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Mineralys Therapeutics Director Daphne Karydas Sells 3,000 Shares for $85,740
Reuters  ·  09-18
Mineralys Therapeutics Director Daphne Karydas Sells 3,000 Shares for $85,740
Mineralys Therapeutics Grants Inducement Equity Awards Covering 52,080 Shares to New Hires
Reuters  ·  09-10
Mineralys Therapeutics Grants Inducement Equity Awards Covering 52,080 Shares to New Hires
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-10
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat
Reuters  ·  08-26
Mineralys Therapeutics Joins Wells Fargo Annual Healthcare Conference Fireside Chat
Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226
Reuters  ·  08-26
Mineralys Chief Commercial Officer Eric Warren Disposes of 7,437 Common Shares Worth $193,226
Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention
Simply Wall St.  ·  08-23
Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--